Authors: Rhiannon Finnie, Future Science Group
Researchers from the Dana-Farber Cancer Institute (MA, USA) have conducted the largest genomic analysis of patients with smoldering multiple myeloma (SMM) to date. SMM is an asymptomatic precursor to multiple myeloma. The results from this study, presented recently at the 59th American Society of Hematology Annual Meeting and Exposition (9–12 December, 2017, GA, USA), are believed to offer a new insight into the biological mechanism that occurs which causes this asymptomatic stage to develop into the symptomatic disease.
The team of researchers, led by Irene Ghobrial, sequenced 186 bone marrow biopsies from patients with SMM, some of whom progressed to multiple myeloma and some of whom did not. The team continued by matching the genomic data with standard analyses of risks of progression provided by current non-genetic clinical biomarkers.